Clinical Trial Update: GYNORYLAQ™-VLINIVAL™: Ψ-Guided Personalized Neoantigen Peptide Vaccine for High-Risk Endometrial Cancer [EARLY_Phase 1]

View source ↗

Summary

An EARLY Phase 1 clinical trial evaluating GYNORYLAQ-VLINIVAL, a Ψ-guided personalized neoantigen peptide vaccine, for high-risk endometrial cancer; the study i…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Endometrial Carcinoma

Drugs mentioned

• GYNORYLAQ-VLINIVAL

Snippet

Sponsor: Biogenea Pharmaceuticals Ltd. | Conditions: Endometrial Carcinoma, Endometrial Carcinoma Stage III | EARLY_Phase 1 | Status: ENROLLING_BY_INVITATION